Tandan R, Taylor R, DiCostanzo D P, Sharma K, Fries T, Roberts J
Department of Pathology, Beth-Israel Medical Center, New York, New York.
Cancer. 1990 Mar 15;65(6):1286-90. doi: 10.1002/1097-0142(19900315)65:6<1286::aid-cncr2820650605>3.0.co;2-8.
Myasthenia gravis (MG) occurs in up to 44% of patients with thymoma. Thirty-three percent of these neoplasms are invasive but extrathoracic disease is rare. Recently, we saw a patient with MG and recurrent, metastasizing mixed lymphoepithelial thymoma, whose disease was resistant to combination chemotherapy and radiotherapy but who responded dramatically to treatment with daily glucocorticoids. Thus, therapy with daily glucocorticoids should be considered in the treatment of invasive or metastatic thymoma associated with MG, including when conventional surgery, radiotherapy, and chemotherapy have failed.
重症肌无力（MG）在高达44%的胸腺瘤患者中出现。这些肿瘤中有33%具有侵袭性，但胸外疾病罕见。最近，我们遇到一名患有MG且复发性、转移性混合淋巴细胞上皮性胸腺瘤的患者，其疾病对联合化疗和放疗耐药，但对每日糖皮质激素治疗反应显著。因此，在治疗与MG相关的侵袭性或转移性胸腺瘤时，应考虑每日糖皮质激素治疗，包括在传统手术、放疗和化疗失败的情况下。
